Takeaways: The decision is especially meaningful for CELYSTRA because Québec is a high-prevalence region for FCS among French Canadians, so public coverage can quickly translate into concentrate...
Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
